Population PKPD of paclitaxel and carboplatin in ovarian cancer patients: A study by the EORTC-PAMM-NDDG

INTRODUCTION: The paclitaxel/carboplatin doublet is standard treatment in advanced ovarian cancer and usually applied following cytoreductive surgery. Paclitaxel displays nonlinear PK, and the exposure-toxicity relationship has been described by threshold-models, whereas the time above a paclitaxel...

詳細記述

保存先:
書誌詳細
主要な著者: Joerger, M, Huitema, A D R, Richel, D J, Dittrich, C, Pavlidis, N, Briasoulis, E, Vermorken, J B, Strocchi, E, Martoni, A, Sorio, R, Sleeboom, H P, Izquierdo, M A, Jodrell, D I, Calvert, A H, Boddy, A, Hollema, H, Féty, R, Van der Vijgh, W J F, Hempel, G, Chatelut, E, Karlsson, M, Tranchand, B, Schrijvers, A H G J, Beijnen, J H, Schellens, J H M
フォーマット: Artigo
言語:Inglês
出版事項: Blackwell Publishing Ltd 2007
主題:
Proceedings of the Dutch Society of Clinical Pharmacology and Biopharmacy meeting of September 27th 2006
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC2203233/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2007.02886_4.x
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料